(Q45303268)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Onintza Sagredo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

María R Pazos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Valentina Satta

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

José A Ramos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Javier Fernández-Ruiz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

14 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuroscience Research

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

1509-1518

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21674569%20AND%20SRC:MED&resulttype=core&format=json

The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.

4 February 2020

cites work

1 reference

Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets.

21 January 2018

1 reference

Minocycline in phenotypic models of Huntington's disease

21 January 2018

1 reference

In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3.

21 January 2018

1 reference

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

21 January 2018

1 reference

Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases.

21 January 2018

1 reference

Replicating Huntington's disease phenotype in experimental animals

21 January 2018

1 reference

3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.

21 January 2018

1 reference

Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription

21 January 2018

1 reference

Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription

21 January 2018

1 reference

Controlled clinical trial of cannabidiol in Huntington's disease

21 January 2018

1 reference

A pilot study using nabilone for symptomatic treatment in Huntington's disease

21 January 2018

1 reference

Mitochondria in Huntington's disease

21 January 2018

1 reference

Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

21 January 2018

1 reference

The endocannabinoid system as a target for the treatment of neuronal damage

21 January 2018

1 reference

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

21 January 2018

1 reference

S-Allylcysteine prevents the rat from 3-nitropropionic acid-induced hyperactivity, early markers of oxidative stress and mitochondrial dysfunction.

21 January 2018

1 reference

Huntington's disease: progress toward effective disease-modifying treatments and a cure

21 January 2018

1 reference

Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats

21 January 2018

1 reference

Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid

21 January 2018

1 reference

Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.

21 January 2018

1 reference

Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease

21 January 2018

1 reference

Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo.

21 January 2018

1 reference

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

21 January 2018

1 reference

Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease

21 January 2018

1 reference

Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1.

21 January 2018

1 reference

Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression

21 January 2018

1 reference

Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum

21 January 2018

1 reference

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

21 January 2018

1 reference

The endocannabinoid system in Huntington's disease.

21 January 2018

1 reference

Emerging strategies for exploiting cannabinoid receptor agonists as medicines

21 January 2018

1 reference

The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum.

21 January 2018

1 reference

Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression

21 January 2018

1 reference

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

21 January 2018

1 reference

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors

21 January 2018

1 reference

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

21 January 2018

1 reference

Neurochemical substrates of rigidity and chorea in Huntington's disease

21 January 2018

1 reference

Biochemical abnormalities and excitotoxicity in Huntington's disease brain.

21 January 2018

1 reference

Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype

21 January 2018

1 reference

Treatment with dehydroepiandrosterone prevents oxidative stress induced by 3-nitropropionic acid in synaptosomes

21 January 2018

1 reference

Acute neuronal injury, excitotoxicity, and the endocannabinoid system

21 January 2018

1 reference

Cannabinoid-based medicines for neurological disorders--clinical evidence

21 January 2018

1 reference

Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases

21 January 2018

1 reference